What's the Problem?
Many skin diseases are due to disorders in our immune system, notably psoriasis, vitiligo and atopic dermatitis, which affect more than 600 million people worldwide. In addition to conventional drug treatments, in recent years biological treatments with monoclonal antibodies have emerged for severe cases of these pathologies, showing very good efficacy. However, they are expensive and are not suitable for cream formulations because they are unstable molecules and too large to penetrate the skin’s layers. Furthermore, due to their systemic administration, they increase the appearance of adverse effects, lowering the defenses of patients and making it impossible to use it in people with a previous disease.